TNO

TNO is a research and technology institute that provides comprehensive capabilities and expertise in predicting and measuring human PK/metabolism. We work with companies and collaborators worldwide, providing innovative and validated in vitro and ex vivo systems to accelerate drug screening and predict/measure bioavailability. This includes InTESTine, an ex-vivo platform using intestinal segments of porcine and human origin to investigate intestinal permeability, predictions on BA and inflammatory responses. Our Gut on a Chip platform enables investigations on host-microbe interactions. The I-screen in vitro platform uses microflora from different origin to investigate microbiome induced drug metabolism. Data on microflora composition changes as SCFA can be generated as well. The Ex-vivo liver platform uses whole perfused livers of porcine/human (NASH) origin addressing biliary excretion, hepatic clearance/metabolism. Comp3/plasma protein binding assay has been especially developed for highly lipophilic compounds. We also perform all Transporter assays (Caco-2, MDCK and HEK-293: uptake/efflux) as well as an Abundance assay to determine the protein expression levels of 20 transporters in one single experiment.

For Human DMPK we have two accelerated mass spectrometer (AMS) systems to conduct microdosing/microtracer AMS studies for candidate selection. Further microdosing can be used to generate absolute BA data and mass balance/MIST (metabolites) reducing and de-risking clinical development.

We look forward to speaking with you and discuss the utility of our technologies.

Preclinical DevelopmentBioanalyticsClinical Pharmacology